Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under co...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychopharmacology (Oxford) 2013-01, Vol.27 (1), p.19-27
Main Authors: Englund, Amir, Morrison, Paul D, Nottage, Judith, Hague, Dominic, Kane, Fergus, Bonaccorso, Stefania, Stone, James M, Reichenberg, Avi, Brenneisen, Rudolf, Holt, David, Feilding, Amanda, Walker, Lucy, Murray, Robin M, Kapur, Shitij
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Cannabidiol - adverse effects
Cannabidiol - pharmacology
Cannabis
Cannabis - adverse effects
Cognitive ability
Cognitive Dysfunction - chemically induced
Cognitive Dysfunction - prevention & control
Controlled conditions
Double-Blind Method
Dronabinol - adverse effects
Dronabinol - antagonists & inhibitors
Drug Interactions
Female
Hippocampus
Hippocampus - drug effects
Humans
Intravenous administration
Learning
Learning - drug effects
Male
Medical sciences
Memory
Memory Disorders - chemically induced
Memory Disorders - prevention & control
Mental disorders
Mental health
Neuropharmacology
Paranoid Disorders - chemically induced
Paranoid Disorders - prevention & control
Pharmacology. Drug treatments
Psychoanalysis
Psychopharmacology
Psychosis
Statistics
Tetrahydrocannabinol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were randomised to receive oral CBD 600mg (n=22) or placebo (n=26), 210 min ahead of intravenous (IV) THC (1.5 mg). Post-THC, there were lower PANSS positive scores in the CBD group, but this did not reach statistical significance. However, clinically significant positive psychotic symptoms (defined a priori as increases ≥3 points) were less likely in the CBD group compared with the placebo group, odds ratio (OR)=0.22 (χ2=4.74, p
ISSN:0269-8811
1461-7285
DOI:10.1177/0269881112460109